Takeda divests TachoSil to Ethicon; deal terminated
Takeda Pharmaceutical Co. Ltd. entered into an agreement to divest its TachoSil fibrin sealant patch and related assets to Johnson & Johnson’s Ethicon Inc. for $400mm in cash.
- Medical Devices
Surgical Equipment & Devices
- Surgical Sealants
- Marketing (Licensing)
- Product Purchase
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.